Personalis Common Stock Net 2018-2024 | PSNL

Personalis common stock net from 2018 to 2024. Common stock net can be defined as the value of common equity ownership.
Personalis Annual Common Stock Net
(Millions of US $)
2023 $0
2022 $0
2021 $0
2020 $0
2019 $0
2018 $0
2017 $0
Personalis Quarterly Common Stock Net
(Millions of US $)
2024-09-30 $0
2024-06-30 $0
2024-03-31 $0
2023-12-31 $0
2023-09-30 $0
2023-06-30 $0
2023-03-31 $0
2022-12-31 $0
2022-09-30 $0
2022-06-30 $0
2022-03-31 $0
2021-12-31 $0
2021-09-30 $0
2021-06-30 $0
2021-03-31 $0
2020-12-31 $0
2020-09-30 $0
2020-06-30 $0
2020-03-31 $0
2019-12-31 $0
2019-09-30 $0
2019-06-30 $0
2019-03-31 $0
2018-12-31
2018-09-30 $0
2018-06-30 $0
2017-12-31 $0
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $0.412B $0.073B
Personalis Inc. is a cancer genomics company. It is engaged in the development of therapies by providing molecular data about each patient's cancer and immune response. Personalis Inc. is based in Menlo Park, California.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $19.441B 7.12
Dr Reddy's Laboratories (RDY) India $11.160B 21.29
BridgeBio Pharma (BBIO) United States $6.858B 0.00
Bausch Health Cos (BHC) Canada $2.354B 1.71
Supernus Pharmaceuticals (SUPN) United States $1.851B 25.20
Amphastar Pharmaceuticals (AMPH) United States $1.501B 9.02
Taysha Gene Therapies (TSHA) United States $0.336B 23.43
Assembly Biosciences (ASMB) United States $0.081B 0.00
Sol-Gel Technologies (SLGL) Israel $0.016B 0.00
Evoke Pharma (EVOK) United States $0.008B 0.00
Teligent (TLGT) United States $0.000B 0.00